Niraparib Combined With Brivanib or Toripalimab in Patients With Cervical Cancer
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
A Clinical Proof-of-concept Study Evaluating Efficacy and Safety of ZL-2306 (Niraparib)
Combined With Brivanib or Toripalimab in Patients With Metastatic, Recurrent, and Persistent
Cervical Cancer